GlassScriptPhysician profile
Kewei Yu
NPI 1619108354
$4,130.59
in general payments reported to CMS, 2019-2025
25 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.16 · 2020: $118 · 2021: $292 · 2022: $682 · 2023: $383 · 2024: $1,960 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Travel and Lodging: $772 · Education: $87.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.24 |
| Travel and Lodging | $772.11 |
| Education | $87.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,091.26 | 2024 | Ha Minuteman G3-R |
| Abbvie INC. | $367.06 | 2022-2025 | Ubrelvy |
| Emd Serono, INC. | $292.12 | 2021-2024 | Mavenclad, Mavenclad |
| Eisai INC. | $241.00 | 2024 | |
| Lundbeck LLC | $180.65 | 2022-2024 | Vyepti |
| Boston Scientific Corporation | $162.71 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $148.33 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $131.68 | 2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $130.95 | 2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $130.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $130.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $126.65 | 2024 | |
| Abbott Laboratories | $125.81 | 2020-2025 | Proclaim |
| Ucb, INC. | $120.00 | 2025 | Nayzilam |
| Cerapedics INC. | $119.00 | 2025 | I-Factor Peptide Enhanced Bone Graft |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $116.93 | 2022 | |
| Impel Pharmaceuticals INC. | $114.92 | 2022 | |
| Medtronic USA, INC. | $113.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $103.37 | 2023 | Farxiga |
| Lilly USA, LLC | $73.30 | 2023 | Emgality, Reyvow, Amyvid |
| Fidia Pharma USA INC. | $34.17 | 2019-2020 | |
| Mml US, INC. | $23.54 | 2025 | Reactiv8 |
| Medtronic, INC. | $21.37 | 2024 | Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $18.70 | 2025 | Crexont |
| Orexo US, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kewei Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.